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Abstract 11 
 Non-covalent PEGylation has great potential for stabilization of therapeutic proteins. Here, 12 
we demonstrated that the non-covalent PEGylation with a PEGylated polyelectrolyte stabilized a 13 
therapeutic protein, L-asparaginase (ASNase). Anionic ASNase and cationic poly(ethylene glycol)-14 
block-poly(N,N-dimethylaminoethyl methacrylate) (PEG-b-PAMA) formed a water-soluble protein–15 
polyelectrolyte complex (PPC) without loss of secondary structure and enzyme activity. PPC with 16 
PEG-b-PAMA successfully inhibited the shaking-induced inactivation and aggregation of ASNase 17 
as well as protease digestion, corresponding to the behaviors of covalently PEGylated ASNase. Thus, 18 
non-covalent PEGylation by PEGylated polyelectrolytes is a new candidate for handling of 19 
therapeutic proteins. 20 
 21 
 22 
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Abbreviations 26 
 L-Asn, L-asparagine; ASNase, L-asparaginase; CD, circular dichroism; DLS, dynamic light 27 
scattering; MOPS, 3-(N-morpholino)propanesulfonic acid; Mw, molecular weight; PAGE, 28 
polyacrylamide gel electrophoresis; PAMA, poly(N,N-dimethylaminoethyl methacrylate); PEG, 29 
poly(ethylene glycol); PEG-ASNase, poly(ethylene glycol)-L-asparaginase; PEG-b-PAMA, 30 
poly(ethylene glycol)-block-poly(N,N-dimethylaminoethyl methacrylate); PMSF, 31 
phenylmethylsulfonyl fluoride; SDS, sodium dodecyl sulfate; TCA, trichloroacetic acid; Tris, 32 
tris(hydroxymethyl)aminomethane 33 
34 
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Introduction 35 
Progress in the fields of recombinant technology and biotechnology have markedly increased 36 
the numbers of therapeutic proteins.
1
 Many therapeutic proteins have large and multi-domain 37 
structures consisting of homo- or heteropolypeptide chains. The formation of quaternary structures is 38 
required for bioactivity of multi-domain enzymes, such as tetrameric L-asparaginase (ASNase), 39 
tetrameric uricase, and trimeric arginase.
2
 In comparison with single-domain proteins, multi-domain 40 
proteins are prone to aggregation and are inactivated by common stresses, such as changes in 41 
temperature, pH shift, and mechanical stress.
3
 Aggregation is the most serious problem for 42 
therapeutic proteins causing loss of their bioactivities, and therefore such aggregates in therapeutic 43 
proteins are generally unacceptable.
4
 Accordingly, a method for stabilization of multi-domain 44 
proteins is important for pharmaceutics. 45 
Covalent attachment of polymers to the protein surface is one strategy for stabilization of 46 
proteins.
3, 5, 6
 Especially, conjugation of poly(ethylene glycol) (PEGylation) is the most promising 47 
method for protein therapy.
7–12
 PEG is a hydrophilic, non-ionic, and non-toxic polymer that provides 48 
a steric shield for proteins, resulting in improvement of the pharmacological properties of the 49 
proteins. In addition, PEGylation also protects proteins against aggregation and protease digestion in 50 
vitro.
13–15
 At present, 12 types of PEGylated therapeutic protein have been approved by the US Food 51 
and Drug Administration,
12
 and are used for several diseases, such as severe combined 52 
immunodeficiency disease, acute lymphoblastic leukemia, and refractory chronic gout.
11
 However, 53 
covalent PEGylation requires chemical reaction for conjugation of PEG to proteins, which is both 54 
time-consuming and costly. 55 
Non-covalent PEGylation has been suggested as an alternative method for stabilizing 56 
proteins using PEG.
16–21
 A common strategy for non-covalent PEGylation involves designing 57 
functional PEG derivatives that bind to proteins. For example, Mueller et al. synthesized several 58 
PEG derivatives conjugated with hydrophobic ligands, which reduced the aggregation of salmon 59 
calcitonin and lysozyme.
17, 18, 21
 Similarly, PEG derivatives conjugated with sugars,
19
 biotin,
16
 and 60 
Page 3 of 25 Journal of Pharmaceutical Sciences
4 
 
nitrilotriacetic acid
20
 have also been designed. However, there have been few studies regarding non-61 
covalent PEGylation of therapeutic proteins. 62 
PEGylated polyelectrolytes are also PEG derivatives. The polyelectrolyte interacts strongly 63 
with complementary charged proteins through multiple electrostatic interactions, resulting in the 64 
formation of various types of protein–polyelectrolyte complex (PPC).
22–28
 We have recently shown 65 
that PEGylated polyelectrolyte could form a water-soluble PPC with α-amylase and β-galactosidase 66 
due to the PEG segment of the polyelectrolyte.
25
 Here, we investigated stabilization of therapeutic 67 
protein through non-covalent PEGylation using PEGylated polyelectrolytes. We selscted ASNase as 68 
a model therapeutic protein which used in acute lymphoblastic leukemia. Anionic ASNase and 69 
cationic poly(ethylene glycol)-block-poly(N,N-dimethylaminoethyl methacrylate) (PEG-b-PAMA) 70 
formed a water-soluble PPC with maintenance of the original secondary structure and enzyme 71 
activity of ASNase. As expected, PEG-b-PAMA protected ASNase against protease digestion and 72 
shaking-induced inactivation. It is important to note that these protective effects of PEG-b-PAMA 73 
were comparable to those of commercial PEGylated ASNase (PEG-ASNase). 74 
75 
Page 4 of 25Journal of Pharmaceutical Sciences
5 
 
Experimental Section 76 
Materials 77 
L-Asparaginase (ASNase) from Escherichia coli was from Kyowa Hakko Kirin Co. Ltd. 78 
(Tokyo, Japan). Nessler’s reagent, 3-(N-morpholino)propanesulfonic acid (MOPS), poly(ethylene 79 
glycol)-L-asparaginase (PEG-ASNase) from Escherichia coli, and trypsin from bovine pancreas 80 
were from Sigma Chemical Co. (St. Louis, MO). Poly(N,N-dimethylaminoethyl methacrylate) 81 
(PAMA) with average molecular weight (Mw) 4.2 kDa, poly(ethylene glycol)-block-poly(N,N-82 
dimethylaminoethyl methacrylate) (PEG-b-PAMA) with average Mw (PEG) 5.0 kDa and Mw 83 
(PAMA) 5.5 kDa were from Polymer Source Inc. (Dorval, QC, Canada). Ammonium sulfate, L-84 
asparagine (L-Asn), poly(ethylene glycol) with average Mw 7.5 kDa, and trichloroacetic acid (TCA) 85 
were from Wako Pure Chemical. Ind., Ltd. (Osaka, Japan). Phenylmethylsulfonyl fluoride (PMSF) 86 
was from Nacalai Tesque (Kyoto, Japan). These chemicals were of high-quality analytical grade and 87 
were used as received. 88 
 89 
 90 
Protein concentrations 91 
The concentrations of proteins were determined from the absorbance at 280 nm using a 92 
spectrophotometer (V-630; Japan Spectroscopic Co., Ltd., Tokyo, Japan) with extinction coefficients 93 
of 94020 M
-1
cm
-1
 (ASNase and PEG-ASNase) or 37650 M
-1
cm
-1
 (trypsin).
29
 94 
 95 
Dynamic light scattering 96 
Dynamic light scattering (DLS) experiments were performed using a Zetasizer Nano ZS light 97 
scattering photometer (Malvern Instruments, Worcestershire, UK) equipped with a 4 mW He-Ne ion 98 
laser (λ = 633 nm). The sizes of the protein with polymer were determined as follows. Solutions 99 
containing 1.0 µM ASNase, 0 – 100 µM polymers, and 10 mM MOPS buffer (pH 7.0) were placed 100 
in a 1-cm path length disposable cuvette, and DLS measurements were performed at 25°C at a 101 
detection angle of 173°. The viscosity of the solutions was approximated by the value of the 10 mM 102 
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MOPS solution (η = 0.87 cP). All results are presented as the averages of three independent 103 
experiments. 104 
 105 
Circular dichroism 106 
Circular dichroism (CD) experiments were performed in a 1-mm path length quartz cuvette 107 
using a J-720 spectropolarimeter (Japan Spectroscopic Co., Ltd., Tokyo, Japan). Solutions 108 
containing 1.0 µM ASNase, 0 – 40 µM polymers, and 10 mM MOPS buffer (pH 7.0) were prepared, 109 
and the spectra were measured at 25°C. The CD spectra of the samples were corrected by 110 
subtracting the corresponding spectra of the buffers in the absence of proteins. 111 
 112 
Enzyme assay 113 
The enzyme activities of ASNase and PEG-ASNase were measured as follows. An aliquot of 114 
50 µL of the protein solution was incubated with 950 µL of the substrate solution containing 22 mM 115 
L-Asn, 10 mM MOPS (pH 7.0) at 37°C for 2.0 min (ASNase) or 10 min (PEG-ASNase). The 116 
reaction was stopped by the addition of 250 µL of 3.0 M TCA in the assay mixture. Subsequently, 117 
the sample was mixed with Nessler’s reagent to measure the ammonia released after L-Asn 118 
hydrolysis. The absorbance was monitored spectrophotometrically at 450 nm. The concentration of 119 
ammonia produced by the enzymatic reaction was determined from a reference curve using 120 
ammonium sulfate as a standard. One unit of enzyme activity was defined as the amount of enzyme 121 
required to produce 1.0 µmol ammonia per min at 37°C. 122 
 123 
Enzyme Degradation of Trypsin 124 
Trypsin solution of 1.0 µM was prepared by dissolving the lyophilized trypsin in cold 1.0 125 
mM HCl. An aliquot of 5.0 µL of trypsin solution was added to 500 µL protein solutions (ASNase: 126 
1.0 µM ASNase, 0 – 40 µM polymers, 10 mM MOPS, pH 7.0; PEG-ASNase: 1.0 µM PEG-ASNase, 127 
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10 mM MOPS, pH 7.0) at 37°C. After incubation for respective periods, enzyme activities of 128 
ASNase were measured by above-mentioned assay. 129 
 130 
Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 131 
An aliquot of 5.0 µL of trypsin solution was added to 500 µL protein solutions (ASNase: 1.0 132 
µM ASNase, 0 – 40 µM polymer, 10 mM MOPS, pH 7.0; PEG-ASNase: 1.0 µM PEG-ASNase, 10 133 
mM MOPS, pH 7.0) at 37°C. After incubation for 2.0 h, 5.0 µL of 100 mM PMSF in ethanol was 134 
added to stop the trypsin digestion reaction. The samples were then mixed with an equal volume of 135 
loading buffer containing 4.0% (w/v) SDS, 20% sucrose, 0.010% (w/v) bromophenol blue, and 125 136 
mM Tris-HCl (pH 6.8). The samples were boiled for 15 min followed by loading on a 14% 137 
polyacrylamide gel with a standard ladder marker, which was obtained from Bio-Rad Laboratories 138 
(Hercules, CA). After gel electrophoresis, the gels were stained with silver nitrate. 139 
 140 
Shaking Treatment 141 
Aliquots of 1.2 mL of protein solutions (ASNase: 1.0 µM ASNase, 0 – 40 µM polymers, 10 142 
mM MOPS, pH 7.0; PEG-ASNase: 1.0 µM PEG-ASNase, 10 mM MOPS, pH 7.0) were added to 143 
2.0-mL microcentrifuge tubes (Thermo Scientific, Waltham, MA). The samples were then shaken at 144 
500 rpm for 0 – 6 hours. The enzyme activities and sizes of the samples were measured by the assay 145 
described above. 146 
 147 
Heat Treatment 148 
Protein solutions (ASNase: 1.0 µM ASNase, 0 – 40 µM polymers, 10 mM MOPS, pH 7.0; 149 
PEG-ASNase: 1.0 µM PEG-ASNase, 10 mM MOPS, pH 7.0) were heated at 60°C for 0 – 2 h. The 150 
enzyme activities and sizes of the samples were measured by the assay described above. 151 
152 
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Results 153 
Preparation and Characterization of ASNase/PEG-b-PAMA Complexes. 154 
Figure 1A shows the chemical structures of polymers used in this study. Cationic 155 
poly(ethylene glycol)-block-poly(N,N-dimethylaminoethyl methacrylate) (PEG-b-PAMA) had PEG 156 
and PAMA regions with average Mw of 5.0 kDa and 5.5 kDa, respectively. Two types of 157 
homopolymer were also used for control experiments: cationic PAMA with an average Mw of 4.2 158 
kDa and non-ionic PEG with an average Mw of 7.5 kDa, which were similar to PEG-b-PAMA. 159 
Anionic L-asparaginase (ASNase), which is used in treatment of acute lymphoblastic leukemia, was 160 
selected as a multi-domain therapeutic protein. 161 
We demonstrated previously that cationic PEGylated polyelectrolytes bind to anionic 162 
proteins, resulting in the formation of water-dispersed protein–polyelectrolyte complexes (PPC).
25
 163 
Therefore, we first prepared a PPC between cationic PEG-b-PAMA and anionic ASNase, as 164 
illustrated in Figure 1B. Figure 2A shows the hydrodynamic diameter (Dh) of ASNase in the absence 165 
or presence of polyelectrolytes. The Dh of ASNase alone was 11.1 nm, but increased to > 1000 nm 166 
with the addition of 1.0 µM PEG-b-PAMA. When further PEG-b-PAMA was added to ASNase 167 
solution, the Dh decreased with increasing concentration of PEG-b-PAMA, and then reached a 168 
plateau of 22 nm at around 40 µM PEG-b-PAMA. In contrast, the Dh of ASNase increased sharply 169 
with increasing concentration of cationic PAMA with a plateau of > 1000 nm at around 30 µM 170 
PAMA. The Dh of PEG-b-PAMA and PAMA alone could not be detected by DLS. These results 171 
indicated that ASNase formed a soluble PPC with PEG-b-PAMA, while ASNase formed an 172 
aggregative PPC with PAMA. 173 
We next characterized the structure and enzyme activity of ASNase in the presence of 174 
polymers. Far-UV circular dichroism (CD) spectra of ASNase in the presence of PEG-b-PAMA and 175 
PEG were identical to those of the native ASNase, whereas those of ASNase in the presence of 176 
PAMA decreased (Figure 2B). These results indicated that PAMA denatured the ASNase in 177 
aggregate form, as shown in Figure 2A. Furthermore, PEG-b-PAMA as well as PEG did not affect 178 
the enzyme activity of ASNase, whereas it decreased in the presence of PAMA (Figure 2C). These 179 
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results indicated that ASNase retained the original properties of secondary structure and enzyme 180 
activity after the formation of a PPC with PEG-b-PAMA. 181 
 182 
Stress Tolerance of ASNase Formed PPC with PEG-b-PAMA. 183 
PEGylation is one of the major strategies to stabilize pharmaceutical proteins in vivo due to 184 
the steric hindrance of PEG segments on the protein surface.
7–12
 It is of interest to determine whether 185 
non-covalent interaction between ASNase and PEG-b-PAMA stabilizes the proteins to the same 186 
extent as in covalently conjugated PEGylated proteins toward various stresses, including proteolytic 187 
degradation, and agitation. Therefore, we prepared commercially available PEG-conjugated L-188 
asparaginase (PEG-ASNase) as a model PEGylated protein. 189 
Figure 3A shows the enzyme activities of ASNase in the absence or presence of polymers 190 
preincubated with trypsin, which hydrolyzes peptide bonds at the carboxyl end of basic amino acids 191 
in the proteins. The residual activity of native ASNase was 15%, indicating that ASNase was 192 
inactivated by trypsin proteolysis. Similarly, ASNase in the presence of PAMA and PEG was 193 
inactivated by trypsin proteolysis. In contrast, the addition of PEG-b-PAMA showed a protective 194 
effect against trypsin proteolysis. The residual activity of ASNase/PEG-b-PAMA was 81%, which 195 
was higher than that of PEG-ASNase (47%). 196 
The proteolytic digestion of ASNase by trypsin was further evaluated by SDS-PAGE (Figure 197 
3B). Without trypsin treatment, only a band of monomeric size (35 kDa) was observed under all 198 
conditions. After trypsin digestion, the band of 35 kDa disappeared in the samples of ASNase alone, 199 
ASNase with PAMA, and ASNase with PEG. In contrast, the band of 35 kDa remained in the 200 
presence of PEG-b-PAMA after trypsin treatment, corresponding with the residual activity (Figure 201 
3A). These results indicated that the PPC with PEG-b-PAMA had a protective effect against 202 
proteolysis by trypsin. 203 
We then evaluated the protective effects of PEGylated polyelectrolyte against shaking. A 204 
solution of native ASNase shaken at 500 rpm for 6 h showed visible suspension and the enzyme 205 
activity disappeared completely (Figure 4). DLS measurements indicated that Dh of native ASNase 206 
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after shaking was > 1000 nm (Table 1), suggesting that the native ASNase was inactivated due to 207 
aggregation induced by shaking. In contrast, the residual activity of ASNase with polymers remained 208 
above 75%, and that of PEG-ASNase remained at 47%. It is interesting to note that Dh of 209 
ASNase/PEG-b-PAMA after shaking remained constant, whereas those of other samples were above 210 
1000 nm (Table 1). These results indicated that the PEGylated polyelectrolytes inhibited shaking-211 
induced protein aggregation. 212 
We finally confirmed the effects of PEGylated polyelectrolyte against heat-induced 213 
inactivation of ASNase. Heating temperature was chosen 60 
o
C because of the ASNase did not 214 
inactivated below 40 
o
C (data not shown). The residual activities of native ASNase and PEG-215 
ASNase were 55% and 38%, respectively (Figure 5). With the addition of non-ionic PEG, there was 216 
a slight change in the residual activity to 60%. In contrast, the addition of cationic polyelectrolytes, 217 
PEG-b-PAMA and PAMA, the enzyme activities decreased about 10%. The ASNase and 218 
polyelectrolyte solutions after heating showed visible aggregates with Dh values > 330 nm (Table 1). 219 
These results suggested that polyelectrolytes accelerated the heat-induced inactivation of ASNase. 220 
221 
Page 10 of 25Journal of Pharmaceutical Sciences
11 
 
Discussion 222 
This study showed stabilization of therapeutic proteins using PEGylated polyelectrolytes, as 223 
summarized below. PEGylated cationic PEG-b-PAMA and anionic ASNase formed soluble 224 
complexes without conformational changes, whereas non-PEGylated PAMA formed aggregative 225 
complexes with conformational changes (Figure 2A,B), corresponding to the results reported 226 
previously.
25
 This is because the electrostatic interactions between proteins and polyelectrolytes are 227 
driving forces that stabilize PPC, which was also supported by the control data in which non-charged 228 
PEG alone did not affect the size of ASNase (Table 1). In is interesting to note that the Dh of 229 
ASNase with PEG-b-PAMA was identical to that of PEG-ASNase (Table 1), suggesting that the 230 
conformation of the PPC with PEG-b-PAMA may be similar to that of PEGylated proteins. 231 
Several authors, including our group, reported previously that cationic polyelectrolytes can 232 
bind to anionic enzymes, resulting in inhibition of enzyme activities.
23, 25, 30, 31
 However, the results 233 
of the present study showed that the enzyme activity of ASNase did not change despite PPC 234 
formation (Figure 2C). This unexpected difference in inhibition of polyelectrolytes may be due to 235 
several factors, such as the types of compounds, pH of the solution, and the method used for enzyme 236 
assay. Although it is difficult to determine whether polyelectrolytes inhibit the enzyme activity, PPC 237 
is more favorable for enzyme activity of ASNase than PEG-ASNase because the covalent 238 
PEGylation produces a decrease in activity of proteins.
7–12
 Under the present experimental condition, 239 
the enzyme activities of native ASNase and PEG-ASNase were about 35 U/mL and 10 U/mL, 240 
respectively. 241 
PEG-conjugated proteins are protected from proteolytic digestion by proteases in vitro and in 242 
vivo. In fact, the residual activity of PEG-ASNase toward trypsin was higher than that of native 243 
ASNase (Figure 3). In this study, PEG-b-PAMA protected ASNase from proteolytic digestion to a 244 
comparable extent to PEG-ASNase, whereas the PAMA and PEG did not (Figure 3). These results 245 
indicated that binding of PEG-b-PAMA to the surface of ASNase provided a shield. We concluded 246 
that the protective mechanism of PPC with PEG-b-PAMA is similar to that of PEGylated proteins, 247 
i.e., steric hindrance of PEG on ASNase/PEG-b-PAMA complex inhibits access to protease. 248 
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Shaking is one of the major causes of protein aggregation.
3, 4
 Aggregation by shaking is 249 
primarily attributable to the contact of proteins and air–water interfaces.
4
 Our results indicated that 250 
native ASNase also formed visible aggregates on shaking stress (Table 1), resulting in inactivation 251 
of the enzyme (Figure 4). In contrast, the solutions of ASNase with polymer and PEG-ASNase were 252 
clear and retained enzyme activity. It is emphasized that the Dh of ASNase/PEG-b-PAMA after 253 
shaking remained constant, even though DLS measurement is sensitive to small amounts of 254 
aggregates. It is possible that the steric hindrance of PEG on the ASNase/PEG-b-PAMA complex 255 
conferred protection from the contact of air–water interfaces for the protease. Thus, PPC with 256 
PEGylated polyelectrolyte is better protected against shaking stress as well as proteolytic digestion 257 
than PEGylated proteins. 258 
The data for heat treatment on ASNase are complex, and it is difficult to understand the 259 
mechanism compared to other types of stress. Briefly, PEG-b-PAMA and PAMA accelerated 260 
irreversible inactivation of ASNase against heat treatment, whereas the others did not (Figure 5). 261 
This result was inconsistent with a previous report in which PEGylated polyelectrolyte stabilized hen 262 
egg white lysozyme against heat-induced inactivation.
22
 We concluded that the inconsistency 263 
resulted from monomeric or oligomeric forms of the proteins as follows. The tetrameric ASNase 264 
loses enzyme activity due to dissociation of subunits during heat treatment at 60°C, and then the 265 
enzyme activity is restored by decreasing temperature due to the re-association of subunits.
13, 32
 266 
Furthermore, the denaturation temperature of ASNase is 62°C, which was independent even in the 267 
presence of polymers. Accordingly, the polyelectrolytes are thought to inhibit the re-association of 268 
ASNase through electrostatic interaction, resulting in irreversible inactivation of ASNase. 269 
In summary, we showed that PEGylated polyelectrolytes stabilize the therapeutic protein, 270 
ASNase. PEG-b-PAMA successfully protected ASNase against trypsin digestion and shaking-271 
induced aggregation due to PPC formation. The stabilizing effects of PPC with PEG-b-PAMA were 272 
similar to those of covalent PEGylated ASNase, suggesting that non-covalent PEGylation occurred 273 
with PEGylated polyelectrolytes. Other therapeutic proteins with multi-domain structures would be 274 
stabilized by PEGylated polyelectrolytes. We believe that complex formation between PEGylated 275 
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polyelectrolytes and proteins will expand the applications of therapeutic proteins, such as 276 
formulation and drug delivery systems. 277 
278 
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Table Legends 360 
Table 1. Hydrodynamic diameters (Dh) of ASNase in the absence or presence of polymers. 361 
Parentheses show polydispersity index (PDI). 362 
363 
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Figure Legends 364 
Figure 1. (A) Chemical structures of polymers. (B) Schematic illustration of PPC with PEG-b-365 
PAMA. 366 
 367 
Figure 2. Characterization of ASNase/PEG-b-PAMA complexes. (A) Hydrodynamic diameter (Dh) 368 
variations of the ASNase in the presence of polymers at various [polymer]/[ASNase] ratios. (B) Far-369 
UV CD spectra of ASNase in the absence or presence of polymers at [ASNase]/[polymer] = 1:40. 370 
(C) Normalized enzyme activity of the ASNase in the absence or presence of polymers at 371 
[ASNase]/[polymer] = 1:40. 372 
 373 
Figure 3. Proteolytic digestion of ASNase with polymer. (A) Residual activity of ASNase with 374 
polymers and PEG-ASNase after trypsin treatment. (B) SDS-PAGE of ASNase/polymer 375 
preincubated with or without trypsin treatment. Lane 1, native ASNase; Lane 2, ASNase/PEG-b-376 
PAMA; Lane 3, ASNase/PAMA; Lane 4, ASNase/PEG; M, standard ladder marker. 377 
 378 
Figure 4. Residual activities of ASNase with polymers and PEG-ASNase after the shaking at 500 379 
rpm for 6 hours. 380 
 381 
Figure 5. Residual activity of ASNase with polymers and PEG-ASNase after heat treatment at 60°C 382 
for 2 hours. 383 
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Tables 1 
Table 1. Hydrodynamic diameters (Dh) of ASNase in the absence or presence of polymers. 2 
Parentheses show polydispersity index (PDI). 3 
Dh (nm)
a 
No Stress Shaking Heating 
No Addition 10.8 ± 0.06 (0.20) > 1000 (0.92) 10.1 ± 0.13 (0.29) 
PEG-b-PAMA 26.2 ± 0.28 (0.46) 28.9 ± 0.38 (0.67) 330 ± 2.61 (0.18) 
PAMA > 1000 (1.00) > 1000 (1.00) > 1000 (0.88) 
PEG 11.3 ± 0.02 (0.22) > 1000 (0.84) 13.3 ± 0.40 (0.47) 
PEG-ASNase 24.5 ± 0.18 (0.25) > 1000 (1.00) 28.0 ± 3.01 (0.59) 
a
 Z-average size. 4 
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Figure 1. (A) Chemical structures of polymers. (B) Schematic illustration of PPC with PEG-b-PAMA.  
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Figure 2. Characterization of ASNase/PEG-b-PAMA complexes. (A) Hydrodynamic diameter (Dh) variations 
of the ASNase in the presence of polymers at various [polymer]/[ASNase] ratios. (B) Far-UV CD spectra of 
ASNase in the absence or presence of polymers at [ASNase]/[polymer] = 1:40. (C) Normalized enzyme 
activity of the ASNase in the absence or presence of polymers at [ASNase]/[polymer] = 1:40.  
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Figure 3. Proteolytic digestion of ASNase with polymer. (A) Residual activity of ASNase with polymers and 
PEG-ASNase after trypsin treatment. (B) SDS-PAGE of ASNase/polymer preincubated with or without 
trypsin treatment. Lane 1, native ASNase; Lane 2, ASNase/PEG-b-PAMA; Lane 3, ASNase/PAMA; Lane 4, 
ASNase/PEG; M, standard ladder marker.  
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Figure 4. Residual activities of ASNase with polymers and PEG-ASNase after the shaking at 500 rpm for 6 
hours.  
79x54mm (300 x 300 DPI)  
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Figure 5. Residual activity of ASNase with polymers and PEG-ASNase after heat treatment at 60°C for 2 
hours.  
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